{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:37:21Z","timestamp":1792791441420,"version":"4.5.0"},"reference-count":49,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,11,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>We genotyped 370 subjects with primary myelofibrosis (PMF) and 148 with postpolycythemia vera\/postessential thrombocythemia (PPV\/PET) MF for mutations of EZH2. Mutational status at diagnosis was correlated with hematologic parameters, clinical manifestations, and outcome. A total of 25 different EZH2 mutations were detected in 5.9% of PMF, 1.2% of PPV-MF, and 9.4% of PET-MF patients; most were exonic heterozygous missense changes. EZH2 mutation coexisted with JAK2V617F or ASXL1 mutation in 12 of 29 (41.4%) and 6 of 27 (22.2%) evaluated patients; TET2 and CBL mutations were found in 2 and 1 patients, respectively. EZH2-mutated PMF patients had significantly higher leukocyte counts, blast-cell counts, and larger spleens at diagnosis, and most of them (52.6%) were in the high-risk International Prognostic Score System (IPSS) category. After a median follow-up of 39 months, 128 patients (25.9%) died, 81 (63.3%) because of leukemia. Leukemia-free survival (LFS) and overall survival (OS) were significantly reduced in EZH2-mutated PMF patients (P = .028 and P &lt; .001, respectively); no such impact was seen for PPV\/PET-MF patients, possibly due to the low number of mutated cases. In multivariate analysis, survival of PMF patients was predicted by IPSS high-risk category, a &lt; 25% JAK2V617F allele burden, and EZH2 mutation status. We conclude that EZH2 mutations are independently associated with shorter survival in patients with PMF.<\/jats:p>","DOI":"10.1182\/blood-2011-06-363424","type":"journal-article","created":{"date-parts":[[2011,9,16]],"date-time":"2011-09-16T07:20:19Z","timestamp":1316157619000},"page":"5227-5234","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":247,"title":["EZH2 mutational status predicts poor survival in myelofibrosis"],"prefix":"10.1182","volume":"118","author":[{"given":"Paola","family":"Guglielmelli","sequence":"first","affiliation":[{"name":"Department of Medical and Surgical Critical Care, Section of Hematology, University of Florence, Florence, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Biamonte","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Critical Care, Section of Hematology, University of Florence, Florence, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joannah","family":"Score","sequence":"additional","affiliation":[{"name":"Wessex Regional Genetics Laboratory, Salisbury, United Kingdom;"},{"name":"Faculty of Medicine, University of Southampton, Southampton, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Hidalgo-Curtis","sequence":"additional","affiliation":[{"name":"Wessex Regional Genetics Laboratory, Salisbury, United Kingdom;"},{"name":"Faculty of Medicine, University of Southampton, Southampton, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Cervantes","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Cl\u00ednic, Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer, University of Barcelona, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Maffioli","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Cl\u00ednic, Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer, University of Barcelona, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana","family":"Fanelli","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Critical Care, Section of Hematology, University of Florence, Florence, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Ernst","sequence":"additional","affiliation":[{"name":"Wessex Regional Genetics Laboratory, Salisbury, United Kingdom;"},{"name":"Universit\u00e4tsklinikum Jena, Jena, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils","family":"Winkelman","sequence":"additional","affiliation":[{"name":"Wessex Regional Genetics Laboratory, Salisbury, United Kingdom;"},{"name":"Universit\u00e4tsklinikum Jena, Jena, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy V.","family":"Jones","sequence":"additional","affiliation":[{"name":"Wessex Regional Genetics Laboratory, Salisbury, United Kingdom;"},{"name":"Faculty of Medicine, University of Southampton, Southampton, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Zoi","sequence":"additional","affiliation":[{"name":"Haematology Research Laboratory, Biomedical Research Foundation, Academy of Athens, Athens, Greece;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Reiter","sequence":"additional","affiliation":[{"name":"III Medizinische Universit\u00e4tsklinik, Medizinische Fakult\u00e4t f\u00fcr Klinische Medizin Mannheim der Universit\u00e4t Heidelberg, Mannheim, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Duncombe","sequence":"additional","affiliation":[{"name":"Department of Haematology, Southampton University Hospitals Trust, Southampton, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Villani","sequence":"additional","affiliation":[{"name":"Unit of Clinical Epidemiology and Centre for the Study of Myelofibrosis, Foundation Policlinico San Matteo, Istituto di Ricovero e Cura a Carattere Scientifico, Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Bosi","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Critical Care, Section of Hematology, University of Florence, Florence, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Barosi","sequence":"additional","affiliation":[{"name":"Unit of Clinical Epidemiology and Centre for the Study of Myelofibrosis, Foundation Policlinico San Matteo, Istituto di Ricovero e Cura a Carattere Scientifico, Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas C. P.","family":"Cross","sequence":"additional","affiliation":[{"name":"Wessex Regional Genetics Laboratory, Salisbury, United Kingdom;"},{"name":"Faculty of Medicine, University of Southampton, Southampton, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro M.","family":"Vannucchi","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Critical Care, Section of Hematology, University of Florence, Florence, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"7037","key":"2019111808005932300_B1","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"issue":"4","key":"2019111808005932300_B2","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"issue":"17","key":"2019111808005932300_B3","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders.","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"issue":"9464","key":"2019111808005932300_B4","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"issue":"3","key":"2019111808005932300_B5","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3322\/caac.20009","article-title":"Advances in understanding and management of myeloproliferative neoplasms.","volume":"59","author":"Vannucchi","year":"2009","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"2019111808005932300_B6","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrc2210","article-title":"Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders.","volume":"7","author":"Levine","year":"2007","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"2019111808005932300_B7","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2007-04-083501","article-title":"Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.","volume":"110","author":"Tefferi","year":"2007","journal-title":"Blood"},{"issue":"12","key":"2019111808005932300_B8","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.","volume":"363","author":"Verstovsek","year":"2010","journal-title":"N Engl J Med"},{"issue":"7","key":"2019111808005932300_B9","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1200\/JCO.2010.32.8021","article-title":"Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis.","volume":"29","author":"Pardanani","year":"2011","journal-title":"J Clin Oncol"},{"issue":"22","key":"2019111808005932300_B10","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa0810069","article-title":"Mutation in TET2 in myeloid cancers.","volume":"360","author":"Delhommeau","year":"2009","journal-title":"N Engl J Med"},{"issue":"11","key":"2019111808005932300_B11","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1038\/leu.2009.141","article-title":"Mutations of ASXL1 gene in myeloproliferative neoplasms.","volume":"23","author":"Carbuccia","year":"2009","journal-title":"Leukemia"},{"issue":"24","key":"2019111808005932300_B12","doi-asserted-by":"crossref","first-page":"6182","DOI":"10.1182\/blood-2008-12-194548","article-title":"Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms.","volume":"113","author":"Grand","year":"2009","journal-title":"Blood"},{"issue":"4","key":"2019111808005932300_B13","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1056\/NEJMc0910063","article-title":"Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms.","volume":"362","author":"Green","year":"2010","journal-title":"N Engl J Med"},{"issue":"7","key":"2019111808005932300_B14","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/leu.2010.99","article-title":"Deletions of the transcription factor Ikaros in myeloproliferative neoplasms.","volume":"24","author":"J\u00e4ger","year":"2010","journal-title":"Leukemia"},{"issue":"8","key":"2019111808005932300_B15","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ng.621","article-title":"Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders.","volume":"42","author":"Ernst","year":"2010","journal-title":"Nat Genet"},{"issue":"8","key":"2019111808005932300_B16","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/ng.620","article-title":"Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes.","volume":"42","author":"Nikoloski","year":"2010","journal-title":"Nat Genet"},{"issue":"2","key":"2019111808005932300_B17","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/ng.518","article-title":"Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin.","volume":"42","author":"Morin","year":"2010","journal-title":"Nat Genet"},{"issue":"49","key":"2019111808005932300_B18","doi-asserted-by":"crossref","first-page":"20980","DOI":"10.1073\/pnas.1012525107","article-title":"Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas.","volume":"107","author":"Sneeringer","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"2019111808005932300_B19","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.leukres.2006.12.002","article-title":"Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT).","volume":"31","author":"Mesa","year":"2007","journal-title":"Leuk Res"},{"issue":"8","key":"2019111808005932300_B20","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1182\/blood-2009-04-216044","article-title":"Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele.","volume":"114","author":"Guglielmelli","year":"2009","journal-title":"Blood"},{"issue":"8","key":"2019111808005932300_B21","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1182\/blood-2005-09-3917","article-title":"Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha.","volume":"107","author":"Jones","year":"2006","journal-title":"Blood"},{"issue":"5","key":"2019111808005932300_B22","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2353\/jmoldx.2008.080015","article-title":"A sensitive detection method for MPLW515L or MPLW515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction.","volume":"10","author":"Pancrazzi","year":"2008","journal-title":"J Mol Diagn"},{"issue":"13","key":"2019111808005932300_B23","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"issue":"4","key":"2019111808005932300_B24","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS Plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status.","volume":"29","author":"Gangat","year":"2011","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111808005932300_B25","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/sj.leu.2405097","article-title":"Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival.","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"},{"issue":"1","key":"2019111808005932300_B26","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3324\/haematol.13721","article-title":"JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis.","volume":"94","author":"Guglielmelli","year":"2009","journal-title":"Haematologica"},{"issue":"5","key":"2019111808005932300_B27","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/leu.2008.72","article-title":"Life expectancy and prognostic factors in the classic BCR\/ABL-negative myeloproliferative disorders.","volume":"22","author":"Cervantes","year":"2008","journal-title":"Leukemia"},{"issue":"3","key":"2019111808005932300_B28","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/sj.leu.2405080","article-title":"Choosing between stem cell therapy and drugs in myelofibrosis.","volume":"22","author":"Kr\u00f6ger","year":"2008","journal-title":"Leukemia"},{"key":"2019111808005932300_B29","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment).","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood"},{"issue":"5","key":"2019111808005932300_B30","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1182\/blood-2005-08-3395","article-title":"V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis.","volume":"107","author":"Campbell","year":"2006","journal-title":"Blood"},{"issue":"12","key":"2019111808005932300_B31","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.1182\/blood-2007-07-099184","article-title":"JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis.","volume":"110","author":"Barosi","year":"2007","journal-title":"Blood"},{"issue":"3","key":"2019111808005932300_B32","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1365-2141.2005.05776.x","article-title":"The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates.","volume":"131","author":"Tefferi","year":"2005","journal-title":"Br J Haematol"},{"issue":"1","key":"2019111808005932300_B33","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/leu.2009.225","article-title":"JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46\/1 haplotype is associated with inferior survival.","volume":"24","author":"Tefferi","year":"2010","journal-title":"Leukemia"},{"issue":"8","key":"2019111808005932300_B34","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1038\/leu.2010.126","article-title":"Frequency and clinical correlates of JAK2 46\/1 (GGCC) haplotype in primary myelofibrosis.","volume":"24","author":"Guglielmelli","year":"2010","journal-title":"Leukemia"},{"issue":"3","key":"2019111808005932300_B35","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1365-2141.2007.06565.x","article-title":"Anaemia characterises patients with myelofibrosis harbouring Mpl mutation.","volume":"137","author":"Guglielmelli","year":"2007","journal-title":"Br J Haematol"},{"key":"2019111808005932300_B36","article-title":"Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients. [published online ahead of print June 21, 2011]","author":"Pardanani","journal-title":"Leukemia"},{"issue":"6","key":"2019111808005932300_B37","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1182\/blood-2010-02-270108","article-title":"Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms.","volume":"116","author":"Oh","year":"2010","journal-title":"Blood"},{"issue":"10","key":"2019111808005932300_B38","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/leu.2010.163","article-title":"LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations.","volume":"24","author":"Pardanani","year":"2010","journal-title":"Leukemia"},{"issue":"6","key":"2019111808005932300_B39","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1038\/leu.2010.77","article-title":"IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms.","volume":"24","author":"Pardanani","year":"2010","journal-title":"Leukemia"},{"issue":"6","key":"2019111808005932300_B40","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/leu.2010.69","article-title":"Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.","volume":"24","author":"Tefferi","year":"2010","journal-title":"Leukemia"},{"issue":"13","key":"2019111808005932300_B41","doi-asserted-by":"crossref","first-page":"4385","DOI":"10.1182\/blood-2007-03-082404","article-title":"New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients.","volume":"110","author":"Haase","year":"2007","journal-title":"Blood"},{"issue":"10","key":"2019111808005932300_B42","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1038\/leu.2010.167","article-title":"Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies.","volume":"24","author":"Makishima","year":"2010","journal-title":"Leukemia"},{"issue":"8","key":"2019111808005932300_B43","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1182\/blood-2010-11-321208","article-title":"Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation.","volume":"117","author":"Yap","year":"2011","journal-title":"Blood"},{"issue":"3","key":"2019111808005932300_B44","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.stem.2010.08.002","article-title":"Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer.","volume":"7","author":"Sauvageau","year":"2010","journal-title":"Cell Stem Cell"},{"issue":"7","key":"2019111808005932300_B45","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/leu.2011.58","article-title":"Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms.","volume":"25","author":"Abdel-Wahab","year":"2011","journal-title":"Leukemia"},{"issue":"12","key":"2019111808005932300_B46","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.3324\/haematol.2010.029306","article-title":"Molecular mechanisms associated with leukaemic transformation of MPL-mutant myeloproliferative neoplasms.","volume":"95","author":"Beer","year":"2010","journal-title":"Haematologica"},{"issue":"26","key":"2019111808005932300_B47","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1056\/NEJMoa1013343","article-title":"Clinical effect of point mutations in myelodysplastic syndromes.","volume":"364","author":"Bejar","year":"2011","journal-title":"N Engl J Med"},{"issue":"19","key":"2019111808005932300_B48","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1182\/blood-2010-03-274704","article-title":"Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value.","volume":"116","author":"Smith","year":"2010","journal-title":"Blood"},{"key":"2019111808005932300_B49","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ccr.2010.07.006","article-title":"EZH2 mutations: mutating the epigenetic machinery in myeloid malignancies.","volume":"18","author":"Abdel-Wahab","year":"2010","journal-title":"Cancer Cell"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/19\/5227\/1344988\/zh804511005227.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/19\/5227\/1344988\/zh804511005227.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T13:16:50Z","timestamp":1574083010000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/118\/19\/5227\/29366\/EZH2-mutational-status-predicts-poor-survival-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,10]]},"references-count":49,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2011,11,10]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-06-363424","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,10]]}}}